nodes	percent_of_prediction	percent_of_DWPC	metapath
Diflunisal—PTGS2—Etoposide—uterine cancer	0.158	0.542	CbGbCtD
Diflunisal—PTGS1—Etoposide—uterine cancer	0.133	0.458	CbGbCtD
Diflunisal—Salicylic acid—AKR1C1—uterine cancer	0.0166	1	CrCbGaD
Diflunisal—UGT1A8—renal system—uterine cancer	0.0139	0.146	CbGeAlD
Diflunisal—PTGS1—oviduct—uterine cancer	0.00994	0.105	CbGeAlD
Diflunisal—PTGS1—artery—uterine cancer	0.00658	0.0693	CbGeAlD
Diflunisal—TTR—renal system—uterine cancer	0.00636	0.067	CbGeAlD
Diflunisal—PTGS2—artery—uterine cancer	0.00629	0.0663	CbGeAlD
Diflunisal—TTR—female reproductive system—uterine cancer	0.0051	0.0537	CbGeAlD
Diflunisal—PTGS2—myometrium—uterine cancer	0.00304	0.032	CbGeAlD
Diflunisal—Syncope—Progesterone—uterine cancer	0.00268	0.00537	CcSEcCtD
Diflunisal—Stevens-Johnson syndrome—Dactinomycin—uterine cancer	0.00268	0.00537	CcSEcCtD
Diflunisal—Flatulence—Medroxyprogesterone Acetate—uterine cancer	0.00267	0.00534	CcSEcCtD
Diflunisal—Tension—Medroxyprogesterone Acetate—uterine cancer	0.00266	0.00532	CcSEcCtD
Diflunisal—Palpitations—Progesterone—uterine cancer	0.00264	0.00529	CcSEcCtD
Diflunisal—Stomatitis—Dactinomycin—uterine cancer	0.00264	0.00528	CcSEcCtD
Diflunisal—Nervousness—Medroxyprogesterone Acetate—uterine cancer	0.00263	0.00527	CcSEcCtD
Diflunisal—Loss of consciousness—Progesterone—uterine cancer	0.00263	0.00526	CcSEcCtD
Diflunisal—Muscle spasms—Medroxyprogesterone Acetate—uterine cancer	0.0026	0.00521	CcSEcCtD
Diflunisal—Chest pain—Progesterone—uterine cancer	0.00255	0.0051	CcSEcCtD
Diflunisal—Agranulocytosis—Dactinomycin—uterine cancer	0.00252	0.00505	CcSEcCtD
Diflunisal—PTGS1—epithelium—uterine cancer	0.0025	0.0263	CbGeAlD
Diflunisal—Angioedema—Medroxyprogesterone Acetate—uterine cancer	0.00248	0.00496	CcSEcCtD
Diflunisal—PTGS1—uterine cervix—uterine cancer	0.00247	0.0261	CbGeAlD
Diflunisal—Confusional state—Progesterone—uterine cancer	0.00246	0.00493	CcSEcCtD
Diflunisal—Anaphylactic shock—Progesterone—uterine cancer	0.00244	0.00489	CcSEcCtD
Diflunisal—Oedema—Progesterone—uterine cancer	0.00244	0.00489	CcSEcCtD
Diflunisal—Vertigo—Medroxyprogesterone Acetate—uterine cancer	0.00243	0.00487	CcSEcCtD
Diflunisal—Syncope—Medroxyprogesterone Acetate—uterine cancer	0.00243	0.00486	CcSEcCtD
Diflunisal—Hepatitis—Dactinomycin—uterine cancer	0.00243	0.00486	CcSEcCtD
Diflunisal—PTGS1—smooth muscle tissue—uterine cancer	0.0024	0.0253	CbGeAlD
Diflunisal—Shock—Progesterone—uterine cancer	0.0024	0.00481	CcSEcCtD
Diflunisal—Palpitations—Medroxyprogesterone Acetate—uterine cancer	0.00239	0.00479	CcSEcCtD
Diflunisal—PTGS2—epithelium—uterine cancer	0.00239	0.0251	CbGeAlD
Diflunisal—Loss of consciousness—Medroxyprogesterone Acetate—uterine cancer	0.00238	0.00477	CcSEcCtD
Diflunisal—PTGS2—uterine cervix—uterine cancer	0.00236	0.0249	CbGeAlD
Diflunisal—Hyperhidrosis—Progesterone—uterine cancer	0.00236	0.00472	CcSEcCtD
Diflunisal—Anorexia—Progesterone—uterine cancer	0.00233	0.00466	CcSEcCtD
Diflunisal—PTGS1—renal system—uterine cancer	0.00231	0.0244	CbGeAlD
Diflunisal—Chest pain—Medroxyprogesterone Acetate—uterine cancer	0.00231	0.00462	CcSEcCtD
Diflunisal—PTGS2—smooth muscle tissue—uterine cancer	0.0023	0.0242	CbGeAlD
Diflunisal—Erythema multiforme—Dactinomycin—uterine cancer	0.0023	0.0046	CcSEcCtD
Diflunisal—Toxic epidermal necrolysis—Etoposide—uterine cancer	0.00229	0.00458	CcSEcCtD
Diflunisal—Cramp muscle—Etoposide—uterine cancer	0.00229	0.00458	CcSEcCtD
Diflunisal—Flushing—Dactinomycin—uterine cancer	0.00225	0.00451	CcSEcCtD
Diflunisal—PTGS1—endometrium—uterine cancer	0.00224	0.0236	CbGeAlD
Diflunisal—Confusional state—Medroxyprogesterone Acetate—uterine cancer	0.00223	0.00446	CcSEcCtD
Diflunisal—PTGS2—renal system—uterine cancer	0.00221	0.0233	CbGeAlD
Diflunisal—Oedema—Medroxyprogesterone Acetate—uterine cancer	0.00221	0.00443	CcSEcCtD
Diflunisal—Anaphylactic shock—Medroxyprogesterone Acetate—uterine cancer	0.00221	0.00443	CcSEcCtD
Diflunisal—Insomnia—Progesterone—uterine cancer	0.00221	0.00442	CcSEcCtD
Diflunisal—Paraesthesia—Progesterone—uterine cancer	0.00219	0.00439	CcSEcCtD
Diflunisal—Dyspnoea—Progesterone—uterine cancer	0.00218	0.00436	CcSEcCtD
Diflunisal—Shock—Medroxyprogesterone Acetate—uterine cancer	0.00218	0.00436	CcSEcCtD
Diflunisal—Somnolence—Progesterone—uterine cancer	0.00217	0.00434	CcSEcCtD
Diflunisal—Thrombocytopenia—Medroxyprogesterone Acetate—uterine cancer	0.00216	0.00433	CcSEcCtD
Diflunisal—PTGS1—mammalian vulva—uterine cancer	0.00216	0.0228	CbGeAlD
Diflunisal—Bronchospasm—Etoposide—uterine cancer	0.00216	0.00432	CcSEcCtD
Diflunisal—Dyspepsia—Progesterone—uterine cancer	0.00215	0.0043	CcSEcCtD
Diflunisal—PTGS2—endometrium—uterine cancer	0.00214	0.0225	CbGeAlD
Diflunisal—Hyperhidrosis—Medroxyprogesterone Acetate—uterine cancer	0.00214	0.00428	CcSEcCtD
Diflunisal—Decreased appetite—Progesterone—uterine cancer	0.00212	0.00425	CcSEcCtD
Diflunisal—Anorexia—Medroxyprogesterone Acetate—uterine cancer	0.00211	0.00422	CcSEcCtD
Diflunisal—Fatigue—Progesterone—uterine cancer	0.0021	0.00421	CcSEcCtD
Diflunisal—Constipation—Progesterone—uterine cancer	0.00209	0.00418	CcSEcCtD
Diflunisal—PTGS1—uterus—uterine cancer	0.00206	0.0217	CbGeAlD
Diflunisal—Feeling abnormal—Progesterone—uterine cancer	0.00201	0.00403	CcSEcCtD
Diflunisal—Insomnia—Medroxyprogesterone Acetate—uterine cancer	0.002	0.004	CcSEcCtD
Diflunisal—Gastrointestinal pain—Progesterone—uterine cancer	0.002	0.00399	CcSEcCtD
Diflunisal—Paraesthesia—Medroxyprogesterone Acetate—uterine cancer	0.00199	0.00397	CcSEcCtD
Diflunisal—Dyspnoea—Medroxyprogesterone Acetate—uterine cancer	0.00197	0.00395	CcSEcCtD
Diflunisal—PTGS2—uterus—uterine cancer	0.00197	0.0208	CbGeAlD
Diflunisal—Somnolence—Medroxyprogesterone Acetate—uterine cancer	0.00197	0.00394	CcSEcCtD
Diflunisal—Dyspepsia—Medroxyprogesterone Acetate—uterine cancer	0.00195	0.0039	CcSEcCtD
Diflunisal—Stevens-Johnson syndrome—Etoposide—uterine cancer	0.00194	0.00388	CcSEcCtD
Diflunisal—Urticaria—Progesterone—uterine cancer	0.00194	0.00388	CcSEcCtD
Diflunisal—Body temperature increased—Progesterone—uterine cancer	0.00193	0.00386	CcSEcCtD
Diflunisal—Eructation—Epirubicin—uterine cancer	0.00193	0.00386	CcSEcCtD
Diflunisal—Renal failure—Etoposide—uterine cancer	0.00192	0.00385	CcSEcCtD
Diflunisal—Decreased appetite—Medroxyprogesterone Acetate—uterine cancer	0.00192	0.00385	CcSEcCtD
Diflunisal—Jaundice—Etoposide—uterine cancer	0.00191	0.00382	CcSEcCtD
Diflunisal—Stomatitis—Etoposide—uterine cancer	0.00191	0.00382	CcSEcCtD
Diflunisal—Fatigue—Medroxyprogesterone Acetate—uterine cancer	0.00191	0.00382	CcSEcCtD
Diflunisal—ALB—lymph node—uterine cancer	0.0019	0.02	CbGeAlD
Diflunisal—Constipation—Medroxyprogesterone Acetate—uterine cancer	0.00189	0.00379	CcSEcCtD
Diflunisal—PTGS1—female reproductive system—uterine cancer	0.00185	0.0195	CbGeAlD
Diflunisal—Agranulocytosis—Etoposide—uterine cancer	0.00183	0.00366	CcSEcCtD
Diflunisal—Feeling abnormal—Medroxyprogesterone Acetate—uterine cancer	0.00182	0.00365	CcSEcCtD
Diflunisal—Gastrointestinal pain—Medroxyprogesterone Acetate—uterine cancer	0.00181	0.00362	CcSEcCtD
Diflunisal—Hypersensitivity—Progesterone—uterine cancer	0.0018	0.0036	CcSEcCtD
Diflunisal—Eructation—Doxorubicin—uterine cancer	0.00178	0.00357	CcSEcCtD
Diflunisal—PTGS2—female reproductive system—uterine cancer	0.00177	0.0187	CbGeAlD
Diflunisal—Urticaria—Medroxyprogesterone Acetate—uterine cancer	0.00176	0.00352	CcSEcCtD
Diflunisal—Asthenia—Progesterone—uterine cancer	0.00175	0.0035	CcSEcCtD
Diflunisal—Body temperature increased—Medroxyprogesterone Acetate—uterine cancer	0.00175	0.0035	CcSEcCtD
Diflunisal—Pruritus—Progesterone—uterine cancer	0.00173	0.00346	CcSEcCtD
Diflunisal—Oedema—Dactinomycin—uterine cancer	0.00172	0.00345	CcSEcCtD
Diflunisal—Thrombocytopenia—Dactinomycin—uterine cancer	0.00169	0.00338	CcSEcCtD
Diflunisal—PTGS1—female gonad—uterine cancer	0.00169	0.0178	CbGeAlD
Diflunisal—PTGS1—vagina—uterine cancer	0.00168	0.0177	CbGeAlD
Diflunisal—Diarrhoea—Progesterone—uterine cancer	0.00167	0.00334	CcSEcCtD
Diflunisal—Erythema multiforme—Etoposide—uterine cancer	0.00166	0.00333	CcSEcCtD
Diflunisal—Anorexia—Dactinomycin—uterine cancer	0.00164	0.00329	CcSEcCtD
Diflunisal—Flushing—Etoposide—uterine cancer	0.00163	0.00326	CcSEcCtD
Diflunisal—Hypersensitivity—Medroxyprogesterone Acetate—uterine cancer	0.00163	0.00326	CcSEcCtD
Diflunisal—Photosensitivity—Epirubicin—uterine cancer	0.00162	0.00325	CcSEcCtD
Diflunisal—Dizziness—Progesterone—uterine cancer	0.00161	0.00323	CcSEcCtD
Diflunisal—PTGS2—female gonad—uterine cancer	0.00161	0.017	CbGeAlD
Diflunisal—PTGS2—vagina—uterine cancer	0.0016	0.0169	CbGeAlD
Diflunisal—Asthenia—Medroxyprogesterone Acetate—uterine cancer	0.00159	0.00318	CcSEcCtD
Diflunisal—Pruritus—Medroxyprogesterone Acetate—uterine cancer	0.00156	0.00313	CcSEcCtD
Diflunisal—Vomiting—Progesterone—uterine cancer	0.00155	0.00311	CcSEcCtD
Diflunisal—Rash—Progesterone—uterine cancer	0.00154	0.00308	CcSEcCtD
Diflunisal—Dermatitis—Progesterone—uterine cancer	0.00154	0.00308	CcSEcCtD
Diflunisal—Headache—Progesterone—uterine cancer	0.00153	0.00306	CcSEcCtD
Diflunisal—Diarrhoea—Medroxyprogesterone Acetate—uterine cancer	0.00151	0.00303	CcSEcCtD
Diflunisal—Dermatitis exfoliative—Epirubicin—uterine cancer	0.00151	0.00302	CcSEcCtD
Diflunisal—Photosensitivity—Doxorubicin—uterine cancer	0.0015	0.003	CcSEcCtD
Diflunisal—Decreased appetite—Dactinomycin—uterine cancer	0.0015	0.003	CcSEcCtD
Diflunisal—Renal impairment—Epirubicin—uterine cancer	0.0015	0.00299	CcSEcCtD
Diflunisal—Fatigue—Dactinomycin—uterine cancer	0.00149	0.00298	CcSEcCtD
Diflunisal—Muscle spasms—Etoposide—uterine cancer	0.00147	0.00294	CcSEcCtD
Diflunisal—Dizziness—Medroxyprogesterone Acetate—uterine cancer	0.00146	0.00293	CcSEcCtD
Diflunisal—Nausea—Progesterone—uterine cancer	0.00145	0.0029	CcSEcCtD
Diflunisal—Gastrointestinal haemorrhage—Epirubicin—uterine cancer	0.00142	0.00285	CcSEcCtD
Diflunisal—Feeling abnormal—Dactinomycin—uterine cancer	0.00142	0.00285	CcSEcCtD
Diflunisal—Gastrointestinal pain—Dactinomycin—uterine cancer	0.00141	0.00282	CcSEcCtD
Diflunisal—Vomiting—Medroxyprogesterone Acetate—uterine cancer	0.00141	0.00281	CcSEcCtD
Diflunisal—Dermatitis exfoliative—Doxorubicin—uterine cancer	0.0014	0.00279	CcSEcCtD
Diflunisal—Rash—Medroxyprogesterone Acetate—uterine cancer	0.00139	0.00279	CcSEcCtD
Diflunisal—Dermatitis—Medroxyprogesterone Acetate—uterine cancer	0.00139	0.00279	CcSEcCtD
Diflunisal—Headache—Medroxyprogesterone Acetate—uterine cancer	0.00139	0.00277	CcSEcCtD
Diflunisal—Renal impairment—Doxorubicin—uterine cancer	0.00138	0.00277	CcSEcCtD
Diflunisal—Vertigo—Etoposide—uterine cancer	0.00137	0.00275	CcSEcCtD
Diflunisal—Body temperature increased—Dactinomycin—uterine cancer	0.00136	0.00273	CcSEcCtD
Diflunisal—Loss of consciousness—Etoposide—uterine cancer	0.00134	0.00269	CcSEcCtD
Diflunisal—Gastrointestinal haemorrhage—Doxorubicin—uterine cancer	0.00132	0.00264	CcSEcCtD
Diflunisal—Nausea—Medroxyprogesterone Acetate—uterine cancer	0.00131	0.00263	CcSEcCtD
Diflunisal—Chest pain—Etoposide—uterine cancer	0.0013	0.00261	CcSEcCtD
Diflunisal—Toxic epidermal necrolysis—Epirubicin—uterine cancer	0.00128	0.00257	CcSEcCtD
Diflunisal—Hypersensitivity—Dactinomycin—uterine cancer	0.00127	0.00254	CcSEcCtD
Diflunisal—Gastritis—Epirubicin—uterine cancer	0.00126	0.00252	CcSEcCtD
Diflunisal—Confusional state—Etoposide—uterine cancer	0.00126	0.00252	CcSEcCtD
Diflunisal—Anaphylactic shock—Etoposide—uterine cancer	0.00125	0.0025	CcSEcCtD
Diflunisal—Asthenia—Dactinomycin—uterine cancer	0.00124	0.00248	CcSEcCtD
Diflunisal—Thrombocytopenia—Etoposide—uterine cancer	0.00122	0.00245	CcSEcCtD
Diflunisal—Hyperhidrosis—Etoposide—uterine cancer	0.00121	0.00242	CcSEcCtD
Diflunisal—Anorexia—Etoposide—uterine cancer	0.00119	0.00238	CcSEcCtD
Diflunisal—Toxic epidermal necrolysis—Doxorubicin—uterine cancer	0.00119	0.00237	CcSEcCtD
Diflunisal—Diarrhoea—Dactinomycin—uterine cancer	0.00118	0.00236	CcSEcCtD
Diflunisal—Gastritis—Doxorubicin—uterine cancer	0.00117	0.00233	CcSEcCtD
Diflunisal—Dysuria—Epirubicin—uterine cancer	0.00115	0.0023	CcSEcCtD
Diflunisal—Photosensitivity reaction—Epirubicin—uterine cancer	0.00112	0.00225	CcSEcCtD
Diflunisal—Paraesthesia—Etoposide—uterine cancer	0.00112	0.00224	CcSEcCtD
Diflunisal—Dyspnoea—Etoposide—uterine cancer	0.00111	0.00223	CcSEcCtD
Diflunisal—Somnolence—Etoposide—uterine cancer	0.00111	0.00222	CcSEcCtD
Diflunisal—Vomiting—Dactinomycin—uterine cancer	0.0011	0.0022	CcSEcCtD
Diflunisal—Stevens-Johnson syndrome—Epirubicin—uterine cancer	0.00109	0.00218	CcSEcCtD
Diflunisal—Rash—Dactinomycin—uterine cancer	0.00109	0.00218	CcSEcCtD
Diflunisal—Decreased appetite—Etoposide—uterine cancer	0.00109	0.00217	CcSEcCtD
Diflunisal—PTGS1—lymph node—uterine cancer	0.00108	0.0114	CbGeAlD
Diflunisal—Renal failure—Epirubicin—uterine cancer	0.00108	0.00216	CcSEcCtD
Diflunisal—Fatigue—Etoposide—uterine cancer	0.00108	0.00215	CcSEcCtD
Diflunisal—Stomatitis—Epirubicin—uterine cancer	0.00107	0.00214	CcSEcCtD
Diflunisal—Jaundice—Epirubicin—uterine cancer	0.00107	0.00214	CcSEcCtD
Diflunisal—Constipation—Etoposide—uterine cancer	0.00107	0.00214	CcSEcCtD
Diflunisal—Dysuria—Doxorubicin—uterine cancer	0.00106	0.00213	CcSEcCtD
Diflunisal—Sweating—Epirubicin—uterine cancer	0.00105	0.00211	CcSEcCtD
Diflunisal—Haematuria—Epirubicin—uterine cancer	0.00105	0.00209	CcSEcCtD
Diflunisal—Photosensitivity reaction—Doxorubicin—uterine cancer	0.00104	0.00208	CcSEcCtD
Diflunisal—PTGS2—lymph node—uterine cancer	0.00104	0.0109	CbGeAlD
Diflunisal—Feeling abnormal—Etoposide—uterine cancer	0.00103	0.00206	CcSEcCtD
Diflunisal—PTGS2—Arachidonic acid metabolism—AKR1C3—uterine cancer	0.00103	0.0105	CbGpPWpGaD
Diflunisal—Nausea—Dactinomycin—uterine cancer	0.00102	0.00205	CcSEcCtD
Diflunisal—Agranulocytosis—Epirubicin—uterine cancer	0.00102	0.00205	CcSEcCtD
Diflunisal—Gastrointestinal pain—Etoposide—uterine cancer	0.00102	0.00204	CcSEcCtD
Diflunisal—PTGS1—Overview of nanoparticle effects—CXCL8—uterine cancer	0.00102	0.0104	CbGpPWpGaD
Diflunisal—Stevens-Johnson syndrome—Doxorubicin—uterine cancer	0.00101	0.00201	CcSEcCtD
Diflunisal—Renal failure—Doxorubicin—uterine cancer	0.000998	0.002	CcSEcCtD
Diflunisal—Urticaria—Etoposide—uterine cancer	0.000992	0.00199	CcSEcCtD
Diflunisal—Stomatitis—Doxorubicin—uterine cancer	0.00099	0.00198	CcSEcCtD
Diflunisal—Jaundice—Doxorubicin—uterine cancer	0.00099	0.00198	CcSEcCtD
Diflunisal—Body temperature increased—Etoposide—uterine cancer	0.000987	0.00198	CcSEcCtD
Diflunisal—Hepatitis—Epirubicin—uterine cancer	0.000985	0.00197	CcSEcCtD
Diflunisal—Sweating—Doxorubicin—uterine cancer	0.000973	0.00195	CcSEcCtD
Diflunisal—Haematuria—Doxorubicin—uterine cancer	0.000968	0.00194	CcSEcCtD
Diflunisal—PTGS1—Phase 1 - Functionalization of compounds—CYP11A1—uterine cancer	0.000959	0.0098	CbGpPWpGaD
Diflunisal—Visual impairment—Epirubicin—uterine cancer	0.000949	0.0019	CcSEcCtD
Diflunisal—Agranulocytosis—Doxorubicin—uterine cancer	0.000947	0.0019	CcSEcCtD
Diflunisal—PTGS1—Selenium Micronutrient Network—GPX3—uterine cancer	0.000938	0.00958	CbGpPWpGaD
Diflunisal—Erythema multiforme—Epirubicin—uterine cancer	0.000931	0.00186	CcSEcCtD
Diflunisal—Hypersensitivity—Etoposide—uterine cancer	0.00092	0.00184	CcSEcCtD
Diflunisal—Tinnitus—Epirubicin—uterine cancer	0.000918	0.00184	CcSEcCtD
Diflunisal—Flushing—Epirubicin—uterine cancer	0.000914	0.00183	CcSEcCtD
Diflunisal—Hepatitis—Doxorubicin—uterine cancer	0.000911	0.00182	CcSEcCtD
Diflunisal—PTGS2—Integrated Pancreatic Cancer Pathway—MAP3K4—uterine cancer	0.000907	0.00927	CbGpPWpGaD
Diflunisal—Asthenia—Etoposide—uterine cancer	0.000896	0.00179	CcSEcCtD
Diflunisal—Pruritus—Etoposide—uterine cancer	0.000883	0.00177	CcSEcCtD
Diflunisal—Visual impairment—Doxorubicin—uterine cancer	0.000878	0.00176	CcSEcCtD
Diflunisal—Erythema multiforme—Doxorubicin—uterine cancer	0.000862	0.00172	CcSEcCtD
Diflunisal—Diarrhoea—Etoposide—uterine cancer	0.000854	0.00171	CcSEcCtD
Diflunisal—Tinnitus—Doxorubicin—uterine cancer	0.00085	0.0017	CcSEcCtD
Diflunisal—Flushing—Doxorubicin—uterine cancer	0.000846	0.00169	CcSEcCtD
Diflunisal—Flatulence—Epirubicin—uterine cancer	0.000845	0.00169	CcSEcCtD
Diflunisal—Tension—Epirubicin—uterine cancer	0.000841	0.00168	CcSEcCtD
Diflunisal—Nervousness—Epirubicin—uterine cancer	0.000833	0.00167	CcSEcCtD
Diflunisal—Dizziness—Etoposide—uterine cancer	0.000825	0.00165	CcSEcCtD
Diflunisal—Muscle spasms—Epirubicin—uterine cancer	0.000824	0.00165	CcSEcCtD
Diflunisal—Vision blurred—Epirubicin—uterine cancer	0.000808	0.00162	CcSEcCtD
Diflunisal—PTGS2—Overview of nanoparticle effects—CXCL8—uterine cancer	0.000806	0.00824	CbGpPWpGaD
Diflunisal—Vomiting—Etoposide—uterine cancer	0.000794	0.00159	CcSEcCtD
Diflunisal—Rash—Etoposide—uterine cancer	0.000787	0.00158	CcSEcCtD
Diflunisal—Dermatitis—Etoposide—uterine cancer	0.000786	0.00157	CcSEcCtD
Diflunisal—Headache—Etoposide—uterine cancer	0.000782	0.00157	CcSEcCtD
Diflunisal—Flatulence—Doxorubicin—uterine cancer	0.000782	0.00156	CcSEcCtD
Diflunisal—Tension—Doxorubicin—uterine cancer	0.000778	0.00156	CcSEcCtD
Diflunisal—Nervousness—Doxorubicin—uterine cancer	0.00077	0.00154	CcSEcCtD
Diflunisal—Vertigo—Epirubicin—uterine cancer	0.00077	0.00154	CcSEcCtD
Diflunisal—Syncope—Epirubicin—uterine cancer	0.000769	0.00154	CcSEcCtD
Diflunisal—UGT1A8—Metabolism—NDUFB11—uterine cancer	0.000764	0.0078	CbGpPWpGaD
Diflunisal—UGT1A8—Metabolism—SRD5A2—uterine cancer	0.000764	0.0078	CbGpPWpGaD
Diflunisal—Muscle spasms—Doxorubicin—uterine cancer	0.000763	0.00153	CcSEcCtD
Diflunisal—ALB—Folate Metabolism—GPX3—uterine cancer	0.000758	0.00775	CbGpPWpGaD
Diflunisal—Palpitations—Epirubicin—uterine cancer	0.000758	0.00152	CcSEcCtD
Diflunisal—Loss of consciousness—Epirubicin—uterine cancer	0.000754	0.00151	CcSEcCtD
Diflunisal—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—uterine cancer	0.000751	0.00768	CbGpPWpGaD
Diflunisal—Vision blurred—Doxorubicin—uterine cancer	0.000748	0.0015	CcSEcCtD
Diflunisal—PTGS2—Selenium Micronutrient Network—GPX3—uterine cancer	0.000744	0.00761	CbGpPWpGaD
Diflunisal—Nausea—Etoposide—uterine cancer	0.000741	0.00148	CcSEcCtD
Diflunisal—Chest pain—Epirubicin—uterine cancer	0.00073	0.00146	CcSEcCtD
Diflunisal—TTR—FOXA2 and FOXA3 transcription factor networks—AKT1—uterine cancer	0.000726	0.00742	CbGpPWpGaD
Diflunisal—Vertigo—Doxorubicin—uterine cancer	0.000713	0.00143	CcSEcCtD
Diflunisal—Syncope—Doxorubicin—uterine cancer	0.000711	0.00142	CcSEcCtD
Diflunisal—PTGS2—Signaling mediated by p38-alpha and p38-beta—ESR1—uterine cancer	0.00071	0.00726	CbGpPWpGaD
Diflunisal—Confusional state—Epirubicin—uterine cancer	0.000706	0.00141	CcSEcCtD
Diflunisal—PTGS1—Phase 1 - Functionalization of compounds—CYP19A1—uterine cancer	0.000705	0.00721	CbGpPWpGaD
Diflunisal—Palpitations—Doxorubicin—uterine cancer	0.000701	0.0014	CcSEcCtD
Diflunisal—Anaphylactic shock—Epirubicin—uterine cancer	0.0007	0.0014	CcSEcCtD
Diflunisal—Oedema—Epirubicin—uterine cancer	0.0007	0.0014	CcSEcCtD
Diflunisal—Loss of consciousness—Doxorubicin—uterine cancer	0.000697	0.0014	CcSEcCtD
Diflunisal—Shock—Epirubicin—uterine cancer	0.000688	0.00138	CcSEcCtD
Diflunisal—Thrombocytopenia—Epirubicin—uterine cancer	0.000685	0.00137	CcSEcCtD
Diflunisal—Hyperhidrosis—Epirubicin—uterine cancer	0.000676	0.00135	CcSEcCtD
Diflunisal—Chest pain—Doxorubicin—uterine cancer	0.000675	0.00135	CcSEcCtD
Diflunisal—Anorexia—Epirubicin—uterine cancer	0.000667	0.00134	CcSEcCtD
Diflunisal—PTGS2—S1P1 pathway—VEGFA—uterine cancer	0.000654	0.00669	CbGpPWpGaD
Diflunisal—Confusional state—Doxorubicin—uterine cancer	0.000653	0.00131	CcSEcCtD
Diflunisal—Oedema—Doxorubicin—uterine cancer	0.000647	0.0013	CcSEcCtD
Diflunisal—Anaphylactic shock—Doxorubicin—uterine cancer	0.000647	0.0013	CcSEcCtD
Diflunisal—Shock—Doxorubicin—uterine cancer	0.000637	0.00128	CcSEcCtD
Diflunisal—Thrombocytopenia—Doxorubicin—uterine cancer	0.000634	0.00127	CcSEcCtD
Diflunisal—Insomnia—Epirubicin—uterine cancer	0.000633	0.00127	CcSEcCtD
Diflunisal—Paraesthesia—Epirubicin—uterine cancer	0.000628	0.00126	CcSEcCtD
Diflunisal—Hyperhidrosis—Doxorubicin—uterine cancer	0.000626	0.00125	CcSEcCtD
Diflunisal—Dyspnoea—Epirubicin—uterine cancer	0.000624	0.00125	CcSEcCtD
Diflunisal—Somnolence—Epirubicin—uterine cancer	0.000622	0.00125	CcSEcCtD
Diflunisal—Anorexia—Doxorubicin—uterine cancer	0.000617	0.00124	CcSEcCtD
Diflunisal—Dyspepsia—Epirubicin—uterine cancer	0.000616	0.00123	CcSEcCtD
Diflunisal—Decreased appetite—Epirubicin—uterine cancer	0.000608	0.00122	CcSEcCtD
Diflunisal—Fatigue—Epirubicin—uterine cancer	0.000603	0.00121	CcSEcCtD
Diflunisal—ALB—Selenium Micronutrient Network—GPX3—uterine cancer	0.000602	0.00616	CbGpPWpGaD
Diflunisal—Constipation—Epirubicin—uterine cancer	0.000598	0.0012	CcSEcCtD
Diflunisal—Insomnia—Doxorubicin—uterine cancer	0.000586	0.00117	CcSEcCtD
Diflunisal—Paraesthesia—Doxorubicin—uterine cancer	0.000581	0.00116	CcSEcCtD
Diflunisal—Dyspnoea—Doxorubicin—uterine cancer	0.000577	0.00116	CcSEcCtD
Diflunisal—Feeling abnormal—Epirubicin—uterine cancer	0.000577	0.00115	CcSEcCtD
Diflunisal—Somnolence—Doxorubicin—uterine cancer	0.000576	0.00115	CcSEcCtD
Diflunisal—Gastrointestinal pain—Epirubicin—uterine cancer	0.000572	0.00115	CcSEcCtD
Diflunisal—PTGS2—Aryl Hydrocarbon Receptor—ESR1—uterine cancer	0.000571	0.00583	CbGpPWpGaD
Diflunisal—Dyspepsia—Doxorubicin—uterine cancer	0.00057	0.00114	CcSEcCtD
Diflunisal—Decreased appetite—Doxorubicin—uterine cancer	0.000563	0.00113	CcSEcCtD
Diflunisal—Fatigue—Doxorubicin—uterine cancer	0.000558	0.00112	CcSEcCtD
Diflunisal—Urticaria—Epirubicin—uterine cancer	0.000556	0.00111	CcSEcCtD
Diflunisal—Constipation—Doxorubicin—uterine cancer	0.000554	0.00111	CcSEcCtD
Diflunisal—Body temperature increased—Epirubicin—uterine cancer	0.000553	0.00111	CcSEcCtD
Diflunisal—UGT1A8—Metabolism—AKR1B1—uterine cancer	0.000552	0.00564	CbGpPWpGaD
Diflunisal—UGT1A8—Metabolism—STAR—uterine cancer	0.000552	0.00564	CbGpPWpGaD
Diflunisal—Feeling abnormal—Doxorubicin—uterine cancer	0.000534	0.00107	CcSEcCtD
Diflunisal—Gastrointestinal pain—Doxorubicin—uterine cancer	0.000529	0.00106	CcSEcCtD
Diflunisal—Hypersensitivity—Epirubicin—uterine cancer	0.000516	0.00103	CcSEcCtD
Diflunisal—Urticaria—Doxorubicin—uterine cancer	0.000514	0.00103	CcSEcCtD
Diflunisal—Body temperature increased—Doxorubicin—uterine cancer	0.000512	0.00102	CcSEcCtD
Diflunisal—PTGS1—Biological oxidations—CYP11A1—uterine cancer	0.000509	0.00521	CbGpPWpGaD
Diflunisal—PTGS2—Integrated Pancreatic Cancer Pathway—INHBA—uterine cancer	0.000507	0.00518	CbGpPWpGaD
Diflunisal—TTR—Disease—AKR1B10—uterine cancer	0.000505	0.00516	CbGpPWpGaD
Diflunisal—Asthenia—Epirubicin—uterine cancer	0.000502	0.00101	CcSEcCtD
Diflunisal—Pruritus—Epirubicin—uterine cancer	0.000495	0.000991	CcSEcCtD
Diflunisal—PTGS1—Selenium Micronutrient Network—MTHFR—uterine cancer	0.000481	0.00492	CbGpPWpGaD
Diflunisal—Diarrhoea—Epirubicin—uterine cancer	0.000479	0.000958	CcSEcCtD
Diflunisal—ALB—Vitamin B12 Metabolism—MTHFR—uterine cancer	0.000478	0.00489	CbGpPWpGaD
Diflunisal—Hypersensitivity—Doxorubicin—uterine cancer	0.000477	0.000955	CcSEcCtD
Diflunisal—Asthenia—Doxorubicin—uterine cancer	0.000465	0.00093	CcSEcCtD
Diflunisal—Dizziness—Epirubicin—uterine cancer	0.000463	0.000926	CcSEcCtD
Diflunisal—Pruritus—Doxorubicin—uterine cancer	0.000458	0.000917	CcSEcCtD
Diflunisal—PTGS1—Metabolism of lipids and lipoproteins—SRD5A2—uterine cancer	0.000452	0.00462	CbGpPWpGaD
Diflunisal—Vomiting—Epirubicin—uterine cancer	0.000445	0.000891	CcSEcCtD
Diflunisal—Diarrhoea—Doxorubicin—uterine cancer	0.000443	0.000887	CcSEcCtD
Diflunisal—Rash—Epirubicin—uterine cancer	0.000441	0.000883	CcSEcCtD
Diflunisal—Dermatitis—Epirubicin—uterine cancer	0.000441	0.000882	CcSEcCtD
Diflunisal—Headache—Epirubicin—uterine cancer	0.000438	0.000878	CcSEcCtD
Diflunisal—UGT1A8—Metabolism—POLD1—uterine cancer	0.000433	0.00443	CbGpPWpGaD
Diflunisal—Dizziness—Doxorubicin—uterine cancer	0.000428	0.000857	CcSEcCtD
Diflunisal—TTR—Disease—RNF43—uterine cancer	0.000419	0.00428	CbGpPWpGaD
Diflunisal—TTR—Extracellular matrix organization—CDH1—uterine cancer	0.000418	0.00427	CbGpPWpGaD
Diflunisal—Nausea—Epirubicin—uterine cancer	0.000416	0.000832	CcSEcCtD
Diflunisal—Vomiting—Doxorubicin—uterine cancer	0.000412	0.000824	CcSEcCtD
Diflunisal—Rash—Doxorubicin—uterine cancer	0.000408	0.000817	CcSEcCtD
Diflunisal—Dermatitis—Doxorubicin—uterine cancer	0.000408	0.000816	CcSEcCtD
Diflunisal—Headache—Doxorubicin—uterine cancer	0.000406	0.000812	CcSEcCtD
Diflunisal—UGT1A8—Metabolism—AKR1C1—uterine cancer	0.000405	0.00414	CbGpPWpGaD
Diflunisal—ALB—Folate Metabolism—MTHFR—uterine cancer	0.000389	0.00398	CbGpPWpGaD
Diflunisal—PTGS2—Aryl Hydrocarbon Receptor—CDKN1B—uterine cancer	0.000388	0.00396	CbGpPWpGaD
Diflunisal—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—MTHFR—uterine cancer	0.000386	0.00394	CbGpPWpGaD
Diflunisal—Nausea—Doxorubicin—uterine cancer	0.000385	0.00077	CcSEcCtD
Diflunisal—SLC22A6—Transmembrane transport of small molecules—ABCC9—uterine cancer	0.000384	0.00393	CbGpPWpGaD
Diflunisal—PTGS2—Selenium Micronutrient Network—MTHFR—uterine cancer	0.000382	0.00391	CbGpPWpGaD
Diflunisal—PTGS1—Selenium Micronutrient Network—CCL2—uterine cancer	0.000377	0.00385	CbGpPWpGaD
Diflunisal—PTGS1—Biological oxidations—CYP19A1—uterine cancer	0.000375	0.00383	CbGpPWpGaD
Diflunisal—ALB—Vitamin B12 Metabolism—CCL2—uterine cancer	0.000374	0.00383	CbGpPWpGaD
Diflunisal—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CXCL8—uterine cancer	0.000372	0.0038	CbGpPWpGaD
Diflunisal—UGT1A8—Metabolism—RRM2—uterine cancer	0.000361	0.00369	CbGpPWpGaD
Diflunisal—PTGS2—Metabolism of lipids and lipoproteins—SRD5A2—uterine cancer	0.000359	0.00367	CbGpPWpGaD
Diflunisal—TTR—Signaling Pathways—AKR1B10—uterine cancer	0.000354	0.00362	CbGpPWpGaD
Diflunisal—UGT1A8—Metabolism—DCN—uterine cancer	0.000351	0.00358	CbGpPWpGaD
Diflunisal—TTR—Disease—AKR1C1—uterine cancer	0.000345	0.00352	CbGpPWpGaD
Diflunisal—PTGS2—Aryl Hydrocarbon Receptor—EP300—uterine cancer	0.000341	0.00348	CbGpPWpGaD
Diflunisal—UGT1A8—Metabolism—CYP11A1—uterine cancer	0.00033	0.00338	CbGpPWpGaD
Diflunisal—PTGS1—Metabolism of lipids and lipoproteins—AKR1B1—uterine cancer	0.000327	0.00334	CbGpPWpGaD
Diflunisal—PTGS1—Metabolism of lipids and lipoproteins—STAR—uterine cancer	0.000327	0.00334	CbGpPWpGaD
Diflunisal—PTGS2—Integrated Pancreatic Cancer Pathway—EZH2—uterine cancer	0.000325	0.00332	CbGpPWpGaD
Diflunisal—PTGS2—Aryl Hydrocarbon Receptor—VEGFA—uterine cancer	0.000323	0.0033	CbGpPWpGaD
Diflunisal—PTGS2—Aryl Hydrocarbon Receptor—NRAS—uterine cancer	0.000319	0.00326	CbGpPWpGaD
Diflunisal—UGT1A8—Metabolism—AKR1C3—uterine cancer	0.000312	0.00319	CbGpPWpGaD
Diflunisal—ALB—Selenium Micronutrient Network—MTHFR—uterine cancer	0.000309	0.00316	CbGpPWpGaD
Diflunisal—ALB—Folate Metabolism—CCL2—uterine cancer	0.000305	0.00311	CbGpPWpGaD
Diflunisal—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—uterine cancer	0.000303	0.0031	CbGpPWpGaD
Diflunisal—PTGS2—Integrated Pancreatic Cancer Pathway—ESR2—uterine cancer	0.000301	0.00308	CbGpPWpGaD
Diflunisal—PTGS2—Selenium Micronutrient Network—CCL2—uterine cancer	0.000299	0.00306	CbGpPWpGaD
Diflunisal—TTR—Disease—DCN—uterine cancer	0.000298	0.00305	CbGpPWpGaD
Diflunisal—TTR—Signaling Pathways—RNF43—uterine cancer	0.000293	0.003	CbGpPWpGaD
Diflunisal—ALB—Metabolism of lipids and lipoproteins—SRD5A2—uterine cancer	0.00029	0.00297	CbGpPWpGaD
Diflunisal—PTGS2—Aryl Hydrocarbon Receptor—KRAS—uterine cancer	0.000274	0.0028	CbGpPWpGaD
Diflunisal—PTGS2—Integrated Pancreatic Cancer Pathway—STK11—uterine cancer	0.000274	0.0028	CbGpPWpGaD
Diflunisal—PTGS2—C-MYB transcription factor network—CDKN2A—uterine cancer	0.000271	0.00277	CbGpPWpGaD
Diflunisal—TTR—Signaling Pathways—INHBA—uterine cancer	0.000268	0.00274	CbGpPWpGaD
Diflunisal—TTR—Disease—AKR1C3—uterine cancer	0.000265	0.00271	CbGpPWpGaD
Diflunisal—PTGS2—Metabolism of lipids and lipoproteins—AKR1B1—uterine cancer	0.00026	0.00265	CbGpPWpGaD
Diflunisal—PTGS2—Metabolism of lipids and lipoproteins—STAR—uterine cancer	0.00026	0.00265	CbGpPWpGaD
Diflunisal—TTR—Disease—HMGA1—uterine cancer	0.000259	0.00264	CbGpPWpGaD
Diflunisal—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN2B—uterine cancer	0.000245	0.00251	CbGpPWpGaD
Diflunisal—UGT1A8—Metabolism—STK11—uterine cancer	0.000243	0.00248	CbGpPWpGaD
Diflunisal—UGT1A8—Metabolism—CYP19A1—uterine cancer	0.000243	0.00248	CbGpPWpGaD
Diflunisal—ALB—Selenium Micronutrient Network—CCL2—uterine cancer	0.000242	0.00247	CbGpPWpGaD
Diflunisal—TTR—Signaling Pathways—AKR1C1—uterine cancer	0.000241	0.00247	CbGpPWpGaD
Diflunisal—PTGS1—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	0.00024	0.00245	CbGpPWpGaD
Diflunisal—PTGS2—C-MYB transcription factor network—CDKN1B—uterine cancer	0.00024	0.00245	CbGpPWpGaD
Diflunisal—TTR—Disease—FBXW7—uterine cancer	0.000237	0.00242	CbGpPWpGaD
Diflunisal—PTGS2—Spinal Cord Injury—CCL2—uterine cancer	0.000236	0.00242	CbGpPWpGaD
Diflunisal—PTGS2—Aryl Hydrocarbon Receptor—HRAS—uterine cancer	0.000233	0.00238	CbGpPWpGaD
Diflunisal—PTGS2—C-MYB transcription factor network—EP300—uterine cancer	0.00021	0.00215	CbGpPWpGaD
Diflunisal—ALB—Metabolism of lipids and lipoproteins—AKR1B1—uterine cancer	0.00021	0.00215	CbGpPWpGaD
Diflunisal—ALB—Metabolism of lipids and lipoproteins—STAR—uterine cancer	0.00021	0.00215	CbGpPWpGaD
Diflunisal—PTGS1—Metabolism—NDUFB11—uterine cancer	0.000201	0.00206	CbGpPWpGaD
Diflunisal—PTGS1—Metabolism—SRD5A2—uterine cancer	0.000201	0.00206	CbGpPWpGaD
Diflunisal—ALB—Transmembrane transport of small molecules—ABCC9—uterine cancer	0.0002	0.00204	CbGpPWpGaD
Diflunisal—PTGS2—C-MYB transcription factor network—NRAS—uterine cancer	0.000197	0.00201	CbGpPWpGaD
Diflunisal—PTGS1—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	0.000196	0.002	CbGpPWpGaD
Diflunisal—PTGS2—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	0.00019	0.00195	CbGpPWpGaD
Diflunisal—PTGS2—Spinal Cord Injury—CXCL8—uterine cancer	0.000187	0.00191	CbGpPWpGaD
Diflunisal—TTR—Signaling Pathways—AKR1C3—uterine cancer	0.000186	0.0019	CbGpPWpGaD
Diflunisal—TTR—Disease—CDKN2B—uterine cancer	0.000185	0.00189	CbGpPWpGaD
Diflunisal—PTGS1—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	0.000185	0.00189	CbGpPWpGaD
Diflunisal—PTGS2—Integrated Pancreatic Cancer Pathway—ESR1—uterine cancer	0.000183	0.00187	CbGpPWpGaD
Diflunisal—UGT1A8—Metabolism—MTHFR—uterine cancer	0.000183	0.00187	CbGpPWpGaD
Diflunisal—PTGS2—Spinal Cord Injury—CDKN1B—uterine cancer	0.000183	0.00187	CbGpPWpGaD
Diflunisal—TTR—Signaling Pathways—PGR—uterine cancer	0.000181	0.00185	CbGpPWpGaD
Diflunisal—TTR—Signaling Pathways—YWHAE—uterine cancer	0.000173	0.00177	CbGpPWpGaD
Diflunisal—ALB—FOXA2 and FOXA3 transcription factor networks—AKT1—uterine cancer	0.000173	0.00176	CbGpPWpGaD
Diflunisal—PTGS2—C-MYB transcription factor network—KRAS—uterine cancer	0.000169	0.00173	CbGpPWpGaD
Diflunisal—TTR—Disease—SMAD3—uterine cancer	0.000169	0.00173	CbGpPWpGaD
Diflunisal—ALB—Platelet degranulation—VEGFA—uterine cancer	0.000168	0.00171	CbGpPWpGaD
Diflunisal—TTR—Signaling Pathways—FBXW7—uterine cancer	0.000166	0.00169	CbGpPWpGaD
Diflunisal—TTR—Disease—FGFR2—uterine cancer	0.000161	0.00165	CbGpPWpGaD
Diflunisal—PTGS2—Metabolism—SRD5A2—uterine cancer	0.00016	0.00163	CbGpPWpGaD
Diflunisal—PTGS2—Metabolism—NDUFB11—uterine cancer	0.00016	0.00163	CbGpPWpGaD
Diflunisal—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—uterine cancer	0.00016	0.00163	CbGpPWpGaD
Diflunisal—TTR—Disease—MTHFR—uterine cancer	0.000155	0.00159	CbGpPWpGaD
Diflunisal—PTGS2—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	0.000155	0.00159	CbGpPWpGaD
Diflunisal—ALB—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	0.000154	0.00157	CbGpPWpGaD
Diflunisal—PTGS2—Disease—AKR1B10—uterine cancer	0.000148	0.00152	CbGpPWpGaD
Diflunisal—ALB—Folate Metabolism—TP53—uterine cancer	0.000148	0.00151	CbGpPWpGaD
Diflunisal—PTGS2—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	0.000147	0.0015	CbGpPWpGaD
Diflunisal—PTGS1—Metabolism—AKR1B1—uterine cancer	0.000146	0.00149	CbGpPWpGaD
Diflunisal—PTGS1—Metabolism—STAR—uterine cancer	0.000146	0.00149	CbGpPWpGaD
Diflunisal—TTR—Signaling Pathways—STK11—uterine cancer	0.000145	0.00148	CbGpPWpGaD
Diflunisal—PTGS2—C-MYB transcription factor network—HRAS—uterine cancer	0.000144	0.00147	CbGpPWpGaD
Diflunisal—PTGS1—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	0.000144	0.00147	CbGpPWpGaD
Diflunisal—TTR—Signaling Pathways—SOCS3—uterine cancer	0.000136	0.00139	CbGpPWpGaD
Diflunisal—PTGS2—Integrated Pancreatic Cancer Pathway—ERBB2—uterine cancer	0.000134	0.00137	CbGpPWpGaD
Diflunisal—TTR—Signaling Pathways—CDKN2B—uterine cancer	0.00013	0.00133	CbGpPWpGaD
Diflunisal—ALB—Hemostasis—IRF1—uterine cancer	0.00013	0.00132	CbGpPWpGaD
Diflunisal—ALB—Metabolism—SRD5A2—uterine cancer	0.000129	0.00132	CbGpPWpGaD
Diflunisal—ALB—Metabolism—NDUFB11—uterine cancer	0.000129	0.00132	CbGpPWpGaD
Diflunisal—TTR—Signaling Pathways—IGF1R—uterine cancer	0.000126	0.00129	CbGpPWpGaD
Diflunisal—ALB—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	0.000126	0.00128	CbGpPWpGaD
Diflunisal—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1B—uterine cancer	0.000124	0.00127	CbGpPWpGaD
Diflunisal—PTGS2—Disease—RNF43—uterine cancer	0.000123	0.00126	CbGpPWpGaD
Diflunisal—ALB—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	0.000119	0.00121	CbGpPWpGaD
Diflunisal—TTR—Signaling Pathways—SMAD3—uterine cancer	0.000119	0.00121	CbGpPWpGaD
Diflunisal—PTGS2—Integrated Pancreatic Cancer Pathway—CTNNB1—uterine cancer	0.000117	0.0012	CbGpPWpGaD
Diflunisal—PTGS2—Metabolism—AKR1B1—uterine cancer	0.000116	0.00118	CbGpPWpGaD
Diflunisal—PTGS2—Metabolism—STAR—uterine cancer	0.000116	0.00118	CbGpPWpGaD
Diflunisal—PTGS2—Spinal Cord Injury—TP53—uterine cancer	0.000115	0.00117	CbGpPWpGaD
Diflunisal—PTGS2—Integrated Pancreatic Cancer Pathway—PTEN—uterine cancer	0.000114	0.00117	CbGpPWpGaD
Diflunisal—PTGS1—Metabolism—POLD1—uterine cancer	0.000114	0.00117	CbGpPWpGaD
Diflunisal—PTGS2—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	0.000114	0.00117	CbGpPWpGaD
Diflunisal—TTR—Signaling Pathways—FGFR2—uterine cancer	0.000113	0.00116	CbGpPWpGaD
Diflunisal—PTGS2—Integrated Pancreatic Cancer Pathway—EP300—uterine cancer	0.000109	0.00111	CbGpPWpGaD
Diflunisal—PTGS1—Metabolism—AKR1C1—uterine cancer	0.000107	0.00109	CbGpPWpGaD
Diflunisal—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—uterine cancer	0.000103	0.00106	CbGpPWpGaD
Diflunisal—UGT1A8—Metabolism—PTEN—uterine cancer	0.000102	0.00104	CbGpPWpGaD
Diflunisal—TTR—Disease—ERBB2—uterine cancer	0.000101	0.00104	CbGpPWpGaD
Diflunisal—PTGS2—Disease—AKR1C1—uterine cancer	0.000101	0.00104	CbGpPWpGaD
Diflunisal—UGT1A8—Metabolism—EP300—uterine cancer	9.69e-05	0.00099	CbGpPWpGaD
Diflunisal—TTR—Signaling Pathways—ESR1—uterine cancer	9.67e-05	0.000988	CbGpPWpGaD
Diflunisal—PTGS1—Metabolism—RRM2—uterine cancer	9.52e-05	0.000973	CbGpPWpGaD
Diflunisal—TTR—Disease—CDKN1B—uterine cancer	9.39e-05	0.000959	CbGpPWpGaD
Diflunisal—ALB—Metabolism—AKR1B1—uterine cancer	9.35e-05	0.000956	CbGpPWpGaD
Diflunisal—ALB—Metabolism—STAR—uterine cancer	9.35e-05	0.000956	CbGpPWpGaD
Diflunisal—PTGS1—Metabolism—DCN—uterine cancer	9.25e-05	0.000945	CbGpPWpGaD
Diflunisal—ALB—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	9.24e-05	0.000945	CbGpPWpGaD
Diflunisal—PTGS2—Metabolism—POLD1—uterine cancer	9.07e-05	0.000927	CbGpPWpGaD
Diflunisal—TTR—Disease—CTNNB1—uterine cancer	8.87e-05	0.000906	CbGpPWpGaD
Diflunisal—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—uterine cancer	8.78e-05	0.000898	CbGpPWpGaD
Diflunisal—PTGS2—Disease—DCN—uterine cancer	8.76e-05	0.000896	CbGpPWpGaD
Diflunisal—PTGS1—Metabolism—CYP11A1—uterine cancer	8.71e-05	0.00089	CbGpPWpGaD
Diflunisal—TTR—Disease—PTEN—uterine cancer	8.64e-05	0.000883	CbGpPWpGaD
Diflunisal—TTR—Signaling Pathways—CCL2—uterine cancer	8.51e-05	0.00087	CbGpPWpGaD
Diflunisal—PTGS2—Metabolism—AKR1C1—uterine cancer	8.48e-05	0.000867	CbGpPWpGaD
Diflunisal—TTR—Disease—EP300—uterine cancer	8.24e-05	0.000842	CbGpPWpGaD
Diflunisal—PTGS1—Metabolism—AKR1C3—uterine cancer	8.23e-05	0.000841	CbGpPWpGaD
Diflunisal—PTGS2—Integrated Pancreatic Cancer Pathway—PIK3CA—uterine cancer	8.07e-05	0.000825	CbGpPWpGaD
Diflunisal—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—uterine cancer	7.8e-05	0.000798	CbGpPWpGaD
Diflunisal—PTGS2—Disease—AKR1C3—uterine cancer	7.8e-05	0.000797	CbGpPWpGaD
Diflunisal—TTR—Disease—NRAS—uterine cancer	7.71e-05	0.000788	CbGpPWpGaD
Diflunisal—PTGS2—Disease—HMGA1—uterine cancer	7.6e-05	0.000777	CbGpPWpGaD
Diflunisal—PTGS2—Metabolism—RRM2—uterine cancer	7.56e-05	0.000773	CbGpPWpGaD
Diflunisal—ALB—Platelet activation, signaling and aggregation—VEGFA—uterine cancer	7.44e-05	0.00076	CbGpPWpGaD
Diflunisal—PTGS2—Metabolism—DCN—uterine cancer	7.34e-05	0.00075	CbGpPWpGaD
Diflunisal—ALB—Metabolism—POLD1—uterine cancer	7.34e-05	0.00075	CbGpPWpGaD
Diflunisal—UGT1A8—Metabolism—PIK3CA—uterine cancer	7.17e-05	0.000732	CbGpPWpGaD
Diflunisal—TTR—Signaling Pathways—ERBB2—uterine cancer	7.1e-05	0.000725	CbGpPWpGaD
Diflunisal—PTGS2—Disease—FBXW7—uterine cancer	6.95e-05	0.00071	CbGpPWpGaD
Diflunisal—PTGS2—Metabolism—CYP11A1—uterine cancer	6.91e-05	0.000707	CbGpPWpGaD
Diflunisal—ALB—Metabolism—AKR1C1—uterine cancer	6.86e-05	0.000701	CbGpPWpGaD
Diflunisal—TTR—Signaling Pathways—CXCL8—uterine cancer	6.73e-05	0.000688	CbGpPWpGaD
Diflunisal—TTR—Disease—KRAS—uterine cancer	6.64e-05	0.000678	CbGpPWpGaD
Diflunisal—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—uterine cancer	6.59e-05	0.000674	CbGpPWpGaD
Diflunisal—TTR—Signaling Pathways—CDKN1B—uterine cancer	6.57e-05	0.000672	CbGpPWpGaD
Diflunisal—PTGS2—Metabolism—AKR1C3—uterine cancer	6.53e-05	0.000667	CbGpPWpGaD
Diflunisal—PTGS1—Metabolism—CYP19A1—uterine cancer	6.41e-05	0.000655	CbGpPWpGaD
Diflunisal—PTGS1—Metabolism—STK11—uterine cancer	6.41e-05	0.000655	CbGpPWpGaD
Diflunisal—TTR—Signaling Pathways—CTNNB1—uterine cancer	6.21e-05	0.000635	CbGpPWpGaD
Diflunisal—ALB—Metabolism—RRM2—uterine cancer	6.12e-05	0.000625	CbGpPWpGaD
Diflunisal—TTR—Disease—PIK3CA—uterine cancer	6.1e-05	0.000623	CbGpPWpGaD
Diflunisal—TTR—Signaling Pathways—PTEN—uterine cancer	6.05e-05	0.000619	CbGpPWpGaD
Diflunisal—PTGS1—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	6.02e-05	0.000615	CbGpPWpGaD
Diflunisal—ALB—Metabolism—DCN—uterine cancer	5.94e-05	0.000607	CbGpPWpGaD
Diflunisal—UGT1A8—Metabolism—AKT1—uterine cancer	5.85e-05	0.000598	CbGpPWpGaD
Diflunisal—ALB—Platelet activation, signaling and aggregation—PIK3CA—uterine cancer	5.81e-05	0.000594	CbGpPWpGaD
Diflunisal—TTR—Signaling Pathways—EP300—uterine cancer	5.77e-05	0.00059	CbGpPWpGaD
Diflunisal—PTGS1—Metabolism of lipids and lipoproteins—EP300—uterine cancer	5.74e-05	0.000586	CbGpPWpGaD
Diflunisal—TTR—Disease—HRAS—uterine cancer	5.64e-05	0.000577	CbGpPWpGaD
Diflunisal—ALB—Metabolism—CYP11A1—uterine cancer	5.59e-05	0.000572	CbGpPWpGaD
Diflunisal—TTR—Signaling Pathways—VEGFA—uterine cancer	5.47e-05	0.000559	CbGpPWpGaD
Diflunisal—PTGS2—Disease—CDKN2B—uterine cancer	5.45e-05	0.000557	CbGpPWpGaD
Diflunisal—TTR—Signaling Pathways—NRAS—uterine cancer	5.4e-05	0.000552	CbGpPWpGaD
Diflunisal—ALB—Metabolism—AKR1C3—uterine cancer	5.28e-05	0.00054	CbGpPWpGaD
Diflunisal—PTGS2—Metabolism—CYP19A1—uterine cancer	5.09e-05	0.00052	CbGpPWpGaD
Diflunisal—PTGS2—Metabolism—STK11—uterine cancer	5.09e-05	0.00052	CbGpPWpGaD
Diflunisal—TTR—Disease—AKT1—uterine cancer	4.98e-05	0.000509	CbGpPWpGaD
Diflunisal—PTGS2—Disease—SMAD3—uterine cancer	4.97e-05	0.000508	CbGpPWpGaD
Diflunisal—PTGS1—Metabolism—MTHFR—uterine cancer	4.82e-05	0.000492	CbGpPWpGaD
Diflunisal—PTGS2—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	4.78e-05	0.000488	CbGpPWpGaD
Diflunisal—ALB—Platelet activation, signaling and aggregation—AKT1—uterine cancer	4.74e-05	0.000485	CbGpPWpGaD
Diflunisal—PTGS2—Disease—FGFR2—uterine cancer	4.74e-05	0.000485	CbGpPWpGaD
Diflunisal—TTR—Signaling Pathways—KRAS—uterine cancer	4.65e-05	0.000475	CbGpPWpGaD
Diflunisal—PTGS2—Disease—MTHFR—uterine cancer	4.56e-05	0.000467	CbGpPWpGaD
Diflunisal—PTGS2—Metabolism of lipids and lipoproteins—EP300—uterine cancer	4.55e-05	0.000465	CbGpPWpGaD
Diflunisal—TTR—Signaling Pathways—PIK3CA—uterine cancer	4.27e-05	0.000436	CbGpPWpGaD
Diflunisal—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	4.24e-05	0.000434	CbGpPWpGaD
Diflunisal—TTR—Signaling Pathways—TP53—uterine cancer	4.13e-05	0.000422	CbGpPWpGaD
Diflunisal—ALB—Metabolism—CYP19A1—uterine cancer	4.12e-05	0.000421	CbGpPWpGaD
Diflunisal—ALB—Metabolism—STK11—uterine cancer	4.12e-05	0.000421	CbGpPWpGaD
Diflunisal—ALB—Hemostasis—EP300—uterine cancer	4.05e-05	0.000414	CbGpPWpGaD
Diflunisal—TTR—Signaling Pathways—HRAS—uterine cancer	3.95e-05	0.000404	CbGpPWpGaD
Diflunisal—ALB—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	3.86e-05	0.000395	CbGpPWpGaD
Diflunisal—ALB—Hemostasis—VEGFA—uterine cancer	3.83e-05	0.000392	CbGpPWpGaD
Diflunisal—PTGS2—Metabolism—MTHFR—uterine cancer	3.82e-05	0.000391	CbGpPWpGaD
Diflunisal—ALB—Hemostasis—NRAS—uterine cancer	3.79e-05	0.000387	CbGpPWpGaD
Diflunisal—ALB—Metabolism of lipids and lipoproteins—EP300—uterine cancer	3.68e-05	0.000377	CbGpPWpGaD
Diflunisal—TTR—Signaling Pathways—AKT1—uterine cancer	3.49e-05	0.000357	CbGpPWpGaD
Diflunisal—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	3.37e-05	0.000344	CbGpPWpGaD
Diflunisal—ALB—Hemostasis—KRAS—uterine cancer	3.26e-05	0.000333	CbGpPWpGaD
Diflunisal—ALB—Metabolism—MTHFR—uterine cancer	3.09e-05	0.000316	CbGpPWpGaD
Diflunisal—ALB—Hemostasis—PIK3CA—uterine cancer	2.99e-05	0.000306	CbGpPWpGaD
Diflunisal—PTGS2—Disease—ERBB2—uterine cancer	2.98e-05	0.000304	CbGpPWpGaD
Diflunisal—ALB—Hemostasis—TP53—uterine cancer	2.9e-05	0.000296	CbGpPWpGaD
Diflunisal—ALB—Hemostasis—HRAS—uterine cancer	2.77e-05	0.000283	CbGpPWpGaD
Diflunisal—PTGS2—Disease—CDKN1B—uterine cancer	2.76e-05	0.000282	CbGpPWpGaD
Diflunisal—ALB—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	2.73e-05	0.000279	CbGpPWpGaD
Diflunisal—PTGS1—Metabolism—PTEN—uterine cancer	2.68e-05	0.000274	CbGpPWpGaD
Diflunisal—PTGS2—Disease—CTNNB1—uterine cancer	2.61e-05	0.000266	CbGpPWpGaD
Diflunisal—PTGS1—Metabolism—EP300—uterine cancer	2.55e-05	0.000261	CbGpPWpGaD
Diflunisal—PTGS2—Disease—PTEN—uterine cancer	2.54e-05	0.00026	CbGpPWpGaD
Diflunisal—ALB—Hemostasis—AKT1—uterine cancer	2.45e-05	0.00025	CbGpPWpGaD
Diflunisal—PTGS2—Disease—EP300—uterine cancer	2.42e-05	0.000248	CbGpPWpGaD
Diflunisal—PTGS2—Disease—NRAS—uterine cancer	2.27e-05	0.000232	CbGpPWpGaD
Diflunisal—PTGS2—Metabolism—PTEN—uterine cancer	2.13e-05	0.000217	CbGpPWpGaD
Diflunisal—PTGS2—Metabolism—EP300—uterine cancer	2.03e-05	0.000207	CbGpPWpGaD
Diflunisal—PTGS2—Disease—KRAS—uterine cancer	1.95e-05	0.000199	CbGpPWpGaD
Diflunisal—PTGS1—Metabolism—PIK3CA—uterine cancer	1.89e-05	0.000193	CbGpPWpGaD
Diflunisal—PTGS2—Disease—PIK3CA—uterine cancer	1.79e-05	0.000183	CbGpPWpGaD
Diflunisal—ALB—Metabolism—PTEN—uterine cancer	1.72e-05	0.000176	CbGpPWpGaD
Diflunisal—PTGS2—Disease—HRAS—uterine cancer	1.66e-05	0.000169	CbGpPWpGaD
Diflunisal—ALB—Metabolism—EP300—uterine cancer	1.64e-05	0.000168	CbGpPWpGaD
Diflunisal—PTGS1—Metabolism—AKT1—uterine cancer	1.54e-05	0.000158	CbGpPWpGaD
Diflunisal—PTGS2—Metabolism—PIK3CA—uterine cancer	1.5e-05	0.000153	CbGpPWpGaD
Diflunisal—PTGS2—Disease—AKT1—uterine cancer	1.46e-05	0.00015	CbGpPWpGaD
Diflunisal—PTGS2—Metabolism—AKT1—uterine cancer	1.23e-05	0.000125	CbGpPWpGaD
Diflunisal—ALB—Metabolism—PIK3CA—uterine cancer	1.21e-05	0.000124	CbGpPWpGaD
Diflunisal—ALB—Metabolism—AKT1—uterine cancer	9.92e-06	0.000101	CbGpPWpGaD
